190 Pompholyx Anne E. Burdick and Ivan D. Camacho Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Pompholyx, also known as dyshidrosis or dyshidrotic eczema, is a recurrent, pruritic vesicular eruption of the palms, soles, and lateral aspects of the fingers. It is of unknown etiology and is considered a reaction pattern to various endogenous and exogenous factors, including atopy, hyperhidrosis, dermatophytosis, contact allergic dermatitis (to nickel, chromium, balsams and cobalt), irritant dermatitis, and possibly emotional stress and seasonal changes. Pompholyx has also been reported to be induced by intravenous immuneglobulin (IVIG) therapy and during the immune reconstitution inflammatory syndrome. Management strategy Although pompholyx may resolve spontaneously, treatment is aimed at controlling pruritus and the formation of vesicular lesions. Evaluation is required to exclude dermatophytosis, irritant or allergic contact dermatitis, impetigo, herpes simplex, and vesiculobullous disorders. Topical corticosteroids are the mainstay of treatment. For mild localized disease, mid- to-high-potency corticosteroid creams or ointments are recommended. Oral antihistamines are useful for control of symptoms. Emollients are also beneficial. A course of oral antibiotics (cephalosporins or doxycycline) is recommended for secondary impetiginization. Topical tacrolimus or pimecrolimus is useful, alone or in combination with a corticosteroid, which may be delivered under occlusion for increased penetration. For severe disease, systemic corticosteroids are indicated: daily prednisone 0.5–1.0 mg/kg/day tapered over 2 weeks, or intramuscular triamcinolone acetonide (40–60 mg). Hand and foot narrowband phototherapy and UVA, alone or with oral or topical psoralen, are also effective. Refractory pompholyx may respond to systemic retinoids such as alitretinoin and immunosuppressive agents including azathioprine, methotrexate, cyclosporine, mycophenolate mofetil or etanercept. Radiotherapy may be an option in recalcitrant cases. Intradermal botulinum toxin A may be helpful as adjuvant therapy. Low nickel and cobalt diets are recommended in nickel-sensitive patients who demonstrate a positive provocation test. Specific investigations Potassium hydroxide preparation Bacterial culture Patch testing Pompholyx eczema as a manifestation of HIV infection, response to antiretroviral therapy. MacConnachie AA, Smith CC. Acta Derm Venereol 2007; 87: 378–9. Pompholyx may present as both a manifestation of symptomatic HIV infection and as part of the immune reconstitution inflammatory syndrome. Conventional treatment for pompholyx may fail but improvement may be observed with highly active antiretroviral therapy. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. J Am Acad Dermatol 2012; 66: 312–16. Pompholyx is observed as an adverse effect in up to 62% of patients receiving IVIG for cutaneous disorders (chronic urticaria, Stevens–Johnson syndrome, Kawasaki syndrome) and neurologic diseases (multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome). Most patients present within 1 to 2 weeks after initiation of IVIG therapy and respond to topical steroids or discontinuation of the medication. A 3-year causative study of pompholyx in 120 patients. Guillet MH, Wierzbicka E, Guillet S, Dagregorio G, Guillet G. Arch Dermatol 2007; 143: 1504–8. A prospective survey of 120 patients reported allergic contact pompholyx in 67.5% of cases (31.7% to cosmetic and hygiene products and 16.7% to metals), 15% idiopathic, 10% secondary to dermatophytes, and 6.7% due to ingestion of drugs, food, or nickel. Role of contact allergens in pompholyx. Jain V, Passi S, Gupta S. J Dermatol 2004; 31: 188–93. Patch testing with the Indian Standard Patch Test Battery was performed on 50 subjects and 40% reacted to one or more allergens. Nickel sulfate was the most common allergen, followed by potassium dichromate, phenylenediamine, nitrofurazone, fragrance mix, and cobalt. Low-cobalt diet for dyshidrotic eczema patients. Stuckert J, Nedorost S. Contact Dermatitis 2008; 59: 361–5. Restriction of dietary cobalt and nickel reduces flares of dyshidrotic eczema, regardless of patch test results. First-line therapies Topical corticosteroids A Topical calcineurin inhibitors C Oral antibiotics D Oral antihistamines E Emollients D Oral corticosteroids D Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: Cat scratch disease Hemangiomas Drug eruptions Erythropoietic protoporphyria Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Stay updated, free articles. Join our Telegram channel Join Tags: Treatment of Skin Disease Comprehensive Therapeutic Strategies Aug 7, 2016 | Posted by admin in Dermatology | Comments Off on Pompholyx Full access? Get Clinical Tree
190 Pompholyx Anne E. Burdick and Ivan D. Camacho Evidence Levels: A Double-blind study B Clinical trial ≥ 20 subjects C Clinical trial < 20 subjects D Series ≥ 5 subjects E Anecdotal case reports Pompholyx, also known as dyshidrosis or dyshidrotic eczema, is a recurrent, pruritic vesicular eruption of the palms, soles, and lateral aspects of the fingers. It is of unknown etiology and is considered a reaction pattern to various endogenous and exogenous factors, including atopy, hyperhidrosis, dermatophytosis, contact allergic dermatitis (to nickel, chromium, balsams and cobalt), irritant dermatitis, and possibly emotional stress and seasonal changes. Pompholyx has also been reported to be induced by intravenous immuneglobulin (IVIG) therapy and during the immune reconstitution inflammatory syndrome. Management strategy Although pompholyx may resolve spontaneously, treatment is aimed at controlling pruritus and the formation of vesicular lesions. Evaluation is required to exclude dermatophytosis, irritant or allergic contact dermatitis, impetigo, herpes simplex, and vesiculobullous disorders. Topical corticosteroids are the mainstay of treatment. For mild localized disease, mid- to-high-potency corticosteroid creams or ointments are recommended. Oral antihistamines are useful for control of symptoms. Emollients are also beneficial. A course of oral antibiotics (cephalosporins or doxycycline) is recommended for secondary impetiginization. Topical tacrolimus or pimecrolimus is useful, alone or in combination with a corticosteroid, which may be delivered under occlusion for increased penetration. For severe disease, systemic corticosteroids are indicated: daily prednisone 0.5–1.0 mg/kg/day tapered over 2 weeks, or intramuscular triamcinolone acetonide (40–60 mg). Hand and foot narrowband phototherapy and UVA, alone or with oral or topical psoralen, are also effective. Refractory pompholyx may respond to systemic retinoids such as alitretinoin and immunosuppressive agents including azathioprine, methotrexate, cyclosporine, mycophenolate mofetil or etanercept. Radiotherapy may be an option in recalcitrant cases. Intradermal botulinum toxin A may be helpful as adjuvant therapy. Low nickel and cobalt diets are recommended in nickel-sensitive patients who demonstrate a positive provocation test. Specific investigations Potassium hydroxide preparation Bacterial culture Patch testing Pompholyx eczema as a manifestation of HIV infection, response to antiretroviral therapy. MacConnachie AA, Smith CC. Acta Derm Venereol 2007; 87: 378–9. Pompholyx may present as both a manifestation of symptomatic HIV infection and as part of the immune reconstitution inflammatory syndrome. Conventional treatment for pompholyx may fail but improvement may be observed with highly active antiretroviral therapy. Pompholyx and eczematous reactions associated with intravenous immunoglobulin therapy. Gerstenblith MR, Antony AK, Junkins-Hopkins JM, Abuav R. J Am Acad Dermatol 2012; 66: 312–16. Pompholyx is observed as an adverse effect in up to 62% of patients receiving IVIG for cutaneous disorders (chronic urticaria, Stevens–Johnson syndrome, Kawasaki syndrome) and neurologic diseases (multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome). Most patients present within 1 to 2 weeks after initiation of IVIG therapy and respond to topical steroids or discontinuation of the medication. A 3-year causative study of pompholyx in 120 patients. Guillet MH, Wierzbicka E, Guillet S, Dagregorio G, Guillet G. Arch Dermatol 2007; 143: 1504–8. A prospective survey of 120 patients reported allergic contact pompholyx in 67.5% of cases (31.7% to cosmetic and hygiene products and 16.7% to metals), 15% idiopathic, 10% secondary to dermatophytes, and 6.7% due to ingestion of drugs, food, or nickel. Role of contact allergens in pompholyx. Jain V, Passi S, Gupta S. J Dermatol 2004; 31: 188–93. Patch testing with the Indian Standard Patch Test Battery was performed on 50 subjects and 40% reacted to one or more allergens. Nickel sulfate was the most common allergen, followed by potassium dichromate, phenylenediamine, nitrofurazone, fragrance mix, and cobalt. Low-cobalt diet for dyshidrotic eczema patients. Stuckert J, Nedorost S. Contact Dermatitis 2008; 59: 361–5. Restriction of dietary cobalt and nickel reduces flares of dyshidrotic eczema, regardless of patch test results. First-line therapies Topical corticosteroids A Topical calcineurin inhibitors C Oral antibiotics D Oral antihistamines E Emollients D Oral corticosteroids D Only gold members can continue reading. Log In or Register to continue Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window) Related Related posts: Cat scratch disease Hemangiomas Drug eruptions Erythropoietic protoporphyria Necrolytic migratory erythema Nevoid basal cell carcinoma syndrome Stay updated, free articles. Join our Telegram channel Join Tags: Treatment of Skin Disease Comprehensive Therapeutic Strategies Aug 7, 2016 | Posted by admin in Dermatology | Comments Off on Pompholyx Full access? Get Clinical Tree